Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality - 2A definitive Bike Standoff: Decision in favor of Your Number one Ride
- 3Figure out How to Establish a long term connection with Your Handshake
- 4RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- 5From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- 8 Espresso Bean Starting points All over the Planet
- Famous Versatile Brands: Your Decision
- Israeli president concerned over proposed renaming of park
- New York to require social media platforms to display mental health warnings
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- Viable Correspondence: Building Solid Connections
- Turning into a Distributed Writer: My Composing Process
